Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?


Drug Profile


Alternative Names: EHT 202; EHT-0202

Latest Information Update: 30 Aug 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator ExonHit Therapeutics
  • Developer Eurobio Scientific; ExonHit Therapeutics
  • Class Antiarrhythmics; Antipsychotics; Nicotinic acids; Pyrazoles; Pyridines; Small molecules
  • Mechanism of Action Amyloid precursor protein secretase inhibitors; GABA A receptor modulators; Type 4 cyclic nucleotide phosphodiesterase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Discontinued Alzheimer's disease; Parkinson's disease; Retinal disorders; Vascular dementia

Most Recent Events

  • 19 Dec 2012 ExonHit Therapeutics has merged with InGen Biosciences to form Diaxonhit
  • 15 Mar 2011 Etazolate is available for licensing as of 15 Mar 2011. http://www.exonhit.com/
  • 30 Oct 2009 Efficacy & adverse events data from a phase IIa trial in Alzheimer's disease presented at the 2nd Conference of Clinical Trials on Alzheimer's Disease (CTAD-2009)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top